Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results

David M. Fleischer, Wayne G. Shreffler, Dianne E. Campbell, Todd D. Green, Sara Anvari, Amal Assa'ad, Philippe Bégin, Kirsten Beyer, J. Andrew Bird, Terri Brown-Whitehorn, Aideen Byrne, Edmond S. Chan, Amarjit Cheema, Sharon Chinthrajah, Hey Jin Chong, Carla M. Davis, Lara S. Ford, Rémi Gagnon, Matthew Greenhawt, Jonathan O.B. HourihaneStacie M. Jones, Edwin H. Kim, Lars Lange, Bruce J. Lanser, Stephanie Leonard, Vera Mahler, Andreas Maronna, Anna Nowak-Wegrzyn, Roxanne C. Oriel, Michael O'Sullivan, Daniel Petroni, Jacqueline A. Pongracic, Susan L. Prescott, Lynda C. Schneider, Peter Smith, Doris Staab, Gordon Sussman, Robert Wood, William H. Yang, Romain Lambert, Aurélie Peillon, Timothée Bois, Hugh A. Sampson

Internal Medicine
Int Med - Chairman's Office
Pediatrics
Allergy & Immunology

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Sort by
Weight
Alphabetically

Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results

Fingerprint

Medicine & Life Sciences